$Petros Pharmaceuticals(PTPI.US)$Petros Pharmaceuticals Inc: Expands Online Distribution for Prescription Stendra(R) (Avanafil) Through New Agreement With Lemonaid Health
$Petros Pharmaceuticals(PTPI.US)$ NEWS Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health
$Petros Pharmaceuticals(PTPI.US)$Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil) 4 MINUTES AGO, 9:15 AM EDT VIA ACCESSWIRE
Petros Pharmaceuticals Takes a Leap Towards OTC Approval with Promising STENDRA(R) Study Results. Petros Pharmaceuticals has shared positive outcomes from a crucial Phase 2-equivalent study for STENDRA(R) (avanafil), marking a significant milestone in the medication's journey towards over-the-counter (OTC) availability. This innovative study paves the way for enhancing accessibility to treatment options for erectile dysfunction (ED), p...
$Petros Pharmaceuticals(PTPI.US)$Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (Avanafil) as It Pursues OTC Status Accesswire· 5 mins ago
$Petros Pharmaceuticals(PTPI.US)$didn't like 1 bit of their 10k filing ... Now i wonder if people already know what will happen to the FDA due to the Massive XL share sales count ... looks to me like grounds for an offering followed by a RS.
Petros Pharmaceuticals股票討論區
NEWS
Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health
4 MINUTES AGO, 9:15 AM EDT
VIA ACCESSWIRE
Petros Pharmaceuticals has shared positive outcomes from a crucial Phase 2-equivalent study for STENDRA(R) (avanafil), marking a significant milestone in the medication's journey towards over-the-counter (OTC) availability. This innovative study paves the way for enhancing accessibility to treatment options for erectile dysfunction (ED), p...
Accesswire· 5 mins ago
暫無評論